Switching from one vaccine product to another can have a significant impact on a country’s budget. For Palestine’s rotavirus vaccination program, a switch paid off. This brief describes an economic analysis conducted by PATH in partnership with the Rostropovich-Vishnevskaya Foundation and the Palestinian Ministry of Health to assess the economic implications of Palestine’s switch from ROTARIX to ROTAVAC.